ProCE Banner Activity


Expert Guidance for Clinical Practice: Implementing CD38 Antibodies for Multiple Myeloma


On-demand webcast of expert-faculty presentation and case discussion on implementing CD38 antibodies in clinical practice to treat patients with multiple myeloma and improve outcomes.

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: January 04, 2024

Expiration: January 03, 2025



Saad Z. Usmani

Saad Z. Usmani, MD, MBA, FACP

Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College, Cornell University
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Sanofi.


Target Audience

This educational program is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients with multiple myeloma.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize the use of anti-CD38 monoclonal antibodies in the treatment of patients with multiple myeloma

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate CD38-targeted antibodies into treatment of patients with transplant-eligible multiple myeloma to improve MRD and OS

  • Apply results of recent clinical trial to treatment selection and sequencing for patients with relapsed/refractory multiple myeloma

  • Appropriately mitigate and manage adverse events associated with CD38 antibody therapy in patients with multiple myeloma

  • Improve awareness of racial and socioeconomic barriers to equitable access to high-quality myeloma care, including clinical trials


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Saad Z. Usmani, MD, MBA, FACP

Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College, Cornell University
New York, New York

Saad Z. Usmani, MD, MBA, FACP: consultant/advisor/speaker: AbbVie, Amgen, Bristol Myers Squibb, Celgene, EdoPharma, Genentech, Gilead, GlaxoSmithKline, Gracell, Janssen, Oncopeptides, Sanofi; researcher: AbbVie, Amgen, Array Biopharma, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Gilead, Janssen, Merck, Pharmacyclics, Sanofi.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Kristi K. Orbaugh, MSN, NP, AOCNP, as noted below.

Kristi K. Orbaugh, MSN, NP, AOCNPconsultant/advisor/speaker: AstraZeneca, Bristol-Myers Squibb, CTI, DSI, Gilead, Lilly, MorphoSys, Pfizer.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from January 04, 2024, through January 03, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008176-0000-24-048-H01-P
Type of Activity: Application

Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.